N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Phase 1 N=21 Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Phase 2 N=57 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Phase 2 N=474 A Study of Atezolizumab in Advanced Solid Tumors
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Phase 2 N=29 M6620 (VX-970) in Selected Solid Tumors
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Phase 1 N=19 Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Phase 1 N=51 Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Part 1 — 0; 0; 1; 1 participants
Phase 1 N=116 A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Advanced Solid Tumors · Advanced Recurrent Ovarian Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants
Phase 1 N=52 Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Advanced Cancer
Primary: Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level — 1; 3; 0; 2 Participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=29 Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Phase 2 N=50 Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Phase 1 N=3 C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Phase 2 N=12 Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Phase 2 N=130 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Phase 1 N=50 Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Melanoma · Metastatic Melanoma · Solid Tumor
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths — 4; 3; 3; 3 Participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Phase 1 N=27 Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Advanced Solid Tumors
Primary: Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) — 0…
Phase 2 N=27 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Phase 1 N=147 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
N/A N=31 Improved Breast MRI With SWIFT
Breast Cancer
Primary: Lesions — 0; 12 lesions
N/A N=70 Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
Sarcoma · Thoracic Cancer · Abdominal Cancer
Primary: Rate of Local Control — 29 Participants